Business
Aap makes a stable start to financial year 2025 - growth in the region with the highest sales EMEA region
Aap makes a stable start to financial year 2025 - growth in the region with the highest sales EMEA
About this update from Aap Implantate Ag
[{"type":"text","content":"\n\n\nEQS-News: aap Implantate AG\n\n\n / Key word(s): Quarterly / Interim Statement\n\n\n\n\n\naap makes a stable start to financial year 2025 - growth in the region with the highest sales EMEA region \n\n\n\n\n\n\n06.05.2025 / 12:25 CET/CEST\n\n\n\nThe issuer is solely responsible for the content of this announcement.Silver: 12-month observation period runs smoothlyQ1 sales show sustained growth in the business Q1 sales form a strong basis for growth in Q2aap Implantate AG (\"aap\" or \"Company\") started the first quarter of 2025 with stable business development. Sales were on a par with the previous year. The EMEA region remained the strongest market region in terms of sales and made a significant contribution to the overall result - with growth both in the core markets and in several non-EU countries, particularly due to the successful placement of new products with US FDA approval.Q1/2025 - SalesTurnover in TEURQ1/2025Q1/2024ChangeEMEA (= Europe, Middle East, Africa)\n 1.702\n 1.456\n +17%North America\n 648\n 731\n -11%LATAM (= Latin America)\n 579\n 788\n -27%APAC (= Asia-Pacific)\n 155\n 149\n +4%Turnover3.0843.124-1%While the first quarter of 2024 was still heavily characterized by set investments, the current result shows a structurally healthier trend: the implant business grew by around 7%, underlining the sustained demand in the core business. This positive development successfully offset the expected declines in the capital goods sector, particularly in the EMEA region.\n\nWithin the EMEA region, South Africa in particular stood out with a strong start to the year, achieving sales growth of around 60% compared to the previous year. The direct sales country Germany grew by 5% despite ongoing structural challenges in the hospital market.\n\nIn the LATAM region, the previous year's growth could not continue. Delayed budget approvals in some distributors' clinics meant that planned orders were cancelled in the first quarter. In contrast, the Mexican market remained stable and was at the previous year's level. The first catch-up orders from other markets were already registered at the beginning of April, which suggests an imminent recovery in the region.\n\nThe company is also carrying orders totaling around € 160,000 into the second quarter. These could not be delivered or collected by 31 March 2025 - partly due to la...